Saba Shafi1, Yan Hu1, Anil V Parwani1, Qingqing Ding2, Zaibo Li3. 1. Department of Pathology, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, Columbus, OH, 43210, USA. 2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 3. Department of Pathology, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, Columbus, OH, 43210, USA. Zaibo.Li@osumc.edu.
Abstract
PURPOSE: The recent WHO classification of breast cancer (2019) categorizes breast carcinoma with neuroendocrine (NE) differentiation into three morphologically distinct subtypes: well-differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine carcinoma (NEC), and invasive breast carcinoma, no special type with neuroendocrine differentiation (IBC-NST-NE). Data regarding the prognostic significance of neuroendocrine differentiation are conflicting and an association, if any, between p53 mutation and neuroendocrine differentiation is largely unknown. METHODS: We examined p53 expression and other clinicopathologic characteristics in three types of invasive breast carcinoma with NE differentiation in a cohort of sixty-three patients, including 45 IBC-NST with NE differentiation, 10 NETs, and 8 NECs. RESULTS: No significant difference of clinicopathologic feature was observed between IBC-NST with NE differentiation and NET, but NECs showed significantly lower expressions of hormone receptors, more mutated p53, and higher frequency of distant metastases than IBC-NST with NE differentiation and NETs. CONCLUSION: NECs of the breast are genetically and clinically different from IBC-NST-NEs and NETs of the breast.
PURPOSE: The recent WHO classification of breast cancer (2019) categorizes breast carcinoma with neuroendocrine (NE) differentiation into three morphologically distinct subtypes: well-differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine carcinoma (NEC), and invasive breast carcinoma, no special type with neuroendocrine differentiation (IBC-NST-NE). Data regarding the prognostic significance of neuroendocrine differentiation are conflicting and an association, if any, between p53 mutation and neuroendocrine differentiation is largely unknown. METHODS: We examined p53 expression and other clinicopathologic characteristics in three types of invasive breast carcinoma with NE differentiation in a cohort of sixty-three patients, including 45 IBC-NST with NE differentiation, 10 NETs, and 8 NECs. RESULTS: No significant difference of clinicopathologic feature was observed between IBC-NST with NE differentiation and NET, but NECs showed significantly lower expressions of hormone receptors, more mutated p53, and higher frequency of distant metastases than IBC-NST with NE differentiation and NETs. CONCLUSION: NECs of the breast are genetically and clinically different from IBC-NST-NEs and NETs of the breast.
Authors: Emad A Rakha; Cecily M Quinn; Maria Pia Foschini; Monica Muñoz Martin; David J Dabbs; Sunil Lakhani; Zsuzsanna Varga; Sarah E Pinder; Fernando C Schmitt; Jorge S Reis-Filho; Stephen B Fox; Ian O Ellis; Puay-Hoon Tan; Raluca Mihai Journal: Histopathology Date: 2020-12-16 Impact factor: 5.087